DGAP-News: STRATEC maintains growth course in first quarter of 2012
(firmenpresse) - DGAP-News: STRATEC Biomedical AG / Key word(s): Quarter
Results/Interim Report
STRATEC maintains growth course in first quarter of 2012
25.04.2012 / 07:25
---------------------------------------------------------------------
STRATEC maintains growth course in first quarter of 2012
- Sales of EUR 25.6 million* in Q1/2012 (+15.5%; Q1/2011: EUR 22.2 million)
- EBIT margin of 17.0%* in Q1/2012 (Q1/2011: 18.0%)
- Consolidated net income of EUR 3.4 million in Q1/2012
(+15.6%; Q1/2011: EUR 3.0 million)
- Earnings per share of EUR 0.29 in Q1/2012 (+11.5%; Q1/2011: EUR 0.26)
- Publication of specific company forecast planned at the
latest by Annual General Meeting on May 16, 2012
Birkenfeld, April 25, 2012
STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) today
announced its figures for the period from January 1, 2012 to March 31, 2012
upon the publication of its interim report as of March 31, 2012.
Key figures (EUR 000s) 01.01.- 03.31.2012 01.01.- 03.31.2011 Change* adjusted for a one-off item due to an earnings-neutral transfer of
Sales 28,841 22,145 +30.2%
Adjusted sales* 25,573 22,145 +15.5%
Overall performance 29,571 25,368 +16.6%
EBITDA 5,324 4,757 +11.9%
EBIT 4,349 3,982 +9.2%
EBIT margin (%)* 17.0 18.0 ---
Consolidated net income 3,439 2,974 +15.6%
Earnings per share (EUR) 0.29 0.26 +11.5%
unfinished services and prepayments received of EUR 3.3 million due to the
impairment of a development project. Unadjusted sales amounted to EUR 28.8
million and the resultant EBIT margin amounted to 15.1%.
Financial performance
The significant growth in STRATEC's sales to EUR 28.8 million (+30.2%) was
mainly driven by the positive performance of systems already established on
the market and by systems launched onto the market in the past 24 months.
This sales figure includes an earnings-neutral transfer of unfinished
services and prepayments received of EUR 3.3 million due to the impairment
of a development project. Excluding this one-off item, sales grew by 15.5%,
and thus within the budgeted framework. The slight decline in the adjusted
EBIT margin to 17% is attributable to a further significant intensification
in development work for additional new system developments, a temporary
weakness in gross profit in the course of a system generation change, and
ramp-up activities for new analyzer systems. At EUR 3.4 million,
consolidated net income was up 15.6% on the previous year's figure and
corresponds to earnings per share of EUR 0.29.
The company plans to specify and extend its current forecast, which
provides for average annual sales growth (CAGR) of 17% in the 2011 to 2013
financial years, with an EBIT margin of at least 19% in 2012 and 2013, at
the latest by its Annual General Meeting on May 16, 2012.
Project development
Further market launches and system approvals are expected in various
regions in the current and following years. To this end, further milestones
have been achieved and measures continue to be taken to extend capacity
within the company's existing structures.
Negotiations are currently underway for several additional new projects,
and have reached advanced stages in some cases. Although it is very
difficult to forecast the timing of new contracts, STRATEC expects to be
able to report on further deals in the coming months.
Other developments
Our customers' forecasts continue not to be affected to any significant
extent by government austerity or fiscal policy measures in the euro and
dollar areas. STRATEC's business model remains largely unconnected to
macroeconomic factors. To date, our talks with customers concerning new and
follow-up projects have not reflected any crisis-induced change in growth
expectations at STRATEC and its partners.
The company's Annual General Meeting is due to be held in Pforzheim/Germany
on May 16, 2012. The Board of Management and Supervisory Board have
proposed a 10% increase in the dividend to EUR 0.55 per share.
Development in staff totals
Including temporary employees, the STRATEC Group had a total of 512
employees as of March 31, 2012 (March 31, 2011: 454). Compared with
December 31, 2011, the workforce has grown by a further 9 employees.
Outlook
Our indicators and forecasts, together with the company's current business
performance, give reason to forecast further growth for 2012 and enable us
to confirm our current guidance figures. At present, our ability to issue
forecasts is temporarily impeded by external factors, such as market
approval by authorities, the dates of further market launches, analyzer
system generation changes, macroeconomic market influences, further
consolidation in the IVD market and planned production ramp-ups for new
systems. We plan to publish a more precise breakdown of our current company
forecast for the 2012 to 2014 financial years at the latest by our Annual
General Meeting on May 16, 2012.
Further details can be found in our Interim Report as of March 31, 2012
published at www.stratec.com>Investor Relations>IR News>Financial
Reports.
About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully
automated analyzer systems for its partners in the fields of clinical
diagnostics and biotechnology. These partners market such systems, in
general together with their own reagents, to laboratories, blood banks and
research institutes around the world. The company develops its products on
the basis of its own patented technologies.
Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard
segment of the Frankfurt Stock Exchange and are listed in the TecDAX select
index of the German Stock Exchange.
Further information can be obtained from:
STRATEC Biomedical AG
AndréLoy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
ir(at)stratec.com
www.stratec.com
End of Corporate News
---------------------------------------------------------------------
25.04.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: STRATEC Biomedical AG
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info(at)stratec.com
Internet: www.stratec.com
ISIN: DE0007289001
WKN: 728900
Indices: TecDAXListed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
166448 25.04.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 25.04.2012 - 01:25 Uhr
Sprache: Deutsch
News-ID 1106824
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 66 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: STRATEC maintains growth course in first quarter of 2012
"
steht unter der journalistisch-redaktionellen Verantwortung von
STRATEC Biomedical AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
